During the months December 2020, January 2021, and February 2021, COVID-19 was the leading cause of death in the United States based on the average number of daily deaths. Heart disease and cancer are usually the number one and number two leading causes of death, respectively. This statistic shows the average number of daily deaths in the United States among the leading causes of death from March 2020 to September 2022.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Summary statistics of average lung cancer incidence rates and average daily smokers in percentage in 8 U.S. geographic regions, 1999–2012.

Although the link between sugar-sweetened beverages (SSB) and pancreatic cancer has been suggested for its insulin-stimulating connection, most epidemiological studies showed inconclusive relationship. Whether the result was limited by sample size is explored. This prospective study followed 491,929 adults, consisting of 235,427 men and 256,502 women (mean age: 39.9, standard deviation: 13.2), from a health surveillance program and there were 523 pancreatic cancer deaths between 1994 and 2017. The individual identification numbers of the cohort were matched with the National Death file for mortality, and Cox models were used to assess the risk. The amount of SSB intake was recorded based on the average consumption in the month before interview by a structured questionnaire. We classified the amount of SSB intake into 4 categories: 0–<0.5 serving/day, ≥0.5–<1 serving per day, ≥1–<2 servings per day, and ≥2 servings per day. One serving was defined as equivalent to 12 oz and contained 35 g added sugar. We used the age and the variables at cohort enrolment as the reported risks of pancreatic cancers. The cohort was divided into 3 age groups, 20–39, 40–59, and ≥60. We found young people (age <40) had higher prevalence and frequency of sugar-sweetened beverages than the elderly. Those consuming 2 servings/day had a 50% increase in pancreatic cancer mortality (HR = 1.55, 95% CI: 1.08–2.24) for the total cohort, but a 3-fold increase (HR: 3.09, 95% CI: 1.44–6.62) for the young. The risk started at 1 serving every other day, with a dose–response relationship. The association of SSB intake of ≥2 servings/day with pancreatic cancer mortality among the total cohort remained significant after excluding those who smoke or have diabetes (HR: 2.12, 97% CI: 1.26–3.57), are obese (HR: 1.57, 95% CI: 1.08–2.30), have hypertension (HR: 1.90, 95% CI: 1.20–3.00), or excluding who died within 3 years after enrollment (HR: 1.67, 95% CI: 1.15–2.45). Risks remained in the sensitivity analyses, implying its independent nature. We concluded that frequent drinking of SSB increased pancreatic cancer in adults, with highest risk among young people.

Summary statistics of mean percentage of daily smokers for males and females in 8 U.S. geographic regions, 1999–2012.

Supporting figures and tables. Figure S1, Prevalence of smoking by age in 1950 birth cohort. Summary of shared input data (used by all 5 models) on smoking patterns for the US cohort born in 1950. Prevalence shown is estimated in the absence of lung cancer mortality. Version 1.0 of the Smoking History Generator (SHG) refers to published data through 2000 (Anderson, et al.), and version 1.5 supplies the 1950 birth cohort used for this analysis with data through 2009 and projections past 2009. Figure S2, Other-cause mortality, by smoking quintile, in 1950 birth cohort. These curves show the other-cause (non-lung cancer) mortality for never smokers and for current smokers by smoking quintile (Q, of cigarettes per day) for the male birth cohort of 1950, out to age 99. Former smokers are intermediate to current and never smokers. There is a similar plot for females. These were shared inputs used by all the models. Note that the rates of non-lung cancer mortality represent the US population, not trial (NLST or PLCO) participants. Figure S3, Prevalence of smoking by age in 1950 birth cohort. Output from one model showing smoking prevalence by age (calendar year), in a no screening scenario. Proportions of current/former/never smokers are in the presence of lung cancer mortality as well as all-cause mortality. Figure S4, Prevalence of smoking by age and pack-years in 1950 birth cohort. Output from one model showing smoking prevalence by category of pack-year and age. The proportion of the cohort by age that has accumulated the specified number of pack-years in the presence of lung cancer mortality and other-cause mortality. Figure S5, Incidence, no screening scenario, output from all models. For predictions past observed SEER data (over age 60) there are no observed data, but we used an age-period-cohort model to project past observed years (‘Projected’ red double line in plots below), which shows that the models are most divergent after age 85, when SEER data become most sparse. We cannot strictly compare incidence to that in prior birth cohorts since smoking patterns are dissimilar, and incidence varies by cohort. Figure S6, Mortality, no screening scenario, output from all models. The vertical line at age 90 indicates age at which all event counts (screens, deaths and deaths averted, and life years gained) were truncated for the analyses reported here. Although the models ranked programs similarly, there was variability in the total numbers of predicted lung cancer cases, deaths, and therefore lung cancer deaths prevented. The differences in rates in the no screening scenario in large part explains the predicted differences between models. The four models (E, F, S, and U) which use two-stage or multi-stage clonal expansion models have more similarly shaped curves than the fifth model (M), which does not use a clonal expansion component (see Table S1 in File S1). Figure S7, Results from all models analogous to Figure 1 in article. Figure S8, Results from all models analogous to Figure 2 in article. Figure S9, Secondary results with reduced operative candidacy with age. The dashed line denotes the efficiency frontier in the main analysis. Table S1, Additional Detail on Models. Table S2, Complete List of 120 Consensus Efficient Scenarios. Table S3, Comparison of Consensus Efficient Scenarios Identified Using Life-years Saved or Lung Cancer Deaths Avoided as Measure of Benefit. (DOCX)

In 2022, the incidence of lung cancer among men in Europe was highest in Hungary at ***** per 100,000, while Sweden had the lowest incidence. The incidence of lung cancer recorded among women in Denmark was over ** per 100,000 population. Across the European Union overall, the rate of lung cancer diagnoses was **** per 100,000 among men and **** per 100,000 among women. Smoking and lung cancer risk The connection between smoking and the increased risk of health problems is well established. As of 2021, Hungary had one of the highest daily smoking rates in Europe, with over a quarter of adults smoking daily in the Central European country. The only other countries with a higher share of smoking adults were Bulgaria and Turkey. A positive development though, is the share of adults smoking every day has decreased in almost every European country since 2011. The rise of vaping Originally marketed as a device to help smokers quit, e-cigarettes or vapes have seen increased popularity among people who never smoked cigarettes, especially young people. The use of vapes among young people was reported to be highest in Estonia, Czechia, and Ireland. The dangers of vaping have not been examined over the long term. In the EU there have been attempts to make ‘vapes’ less accessible and appealing for young people, which would include such things as banning flavors and stopping the sale of disposable e-cigarettes.

In 2023, the number of deaths from cancer in Spain totaled more than ******* deceases. That year, around ****** individuals died from trachea, bronchus, and lung cancer. This type of cancer is highly associated with smoking. As of 2022, the share of daily smokers in Spain amounted to ** percent of the population.

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

Introduction

New York, NY – January 10, 2025 –  Global Histology and Cytology Market size is expected to be worth around US$ 70.1 Billion by 2033 from US$ 18.1 Billion in 2023, growing at a CAGR of 14.5% during the forecast period from 2024 to 2033. In 2023, North America led the market, achieving over 41.1% share with a revenue of US$ 7.4 billion.

The increasing prevalence of cancer and other chronic diseases is a major driver of market growth. The rising demand for personalized medicine, coupled with advancements in cytology and histology tools, further strengthens market dynamics. Key industry players are focusing on developing advanced digital pathology systems and workflow solutions to enhance the accuracy and efficiency of disease diagnosis. Moreover, substantial investments in research are directed toward the development of novel biomarkers and immunohistochemistry assays, enabling improved diagnostic and treatment monitoring. These innovations are expected to create significant growth opportunities during the forecast period.

The growing incidence of chronic diseases, particularly cancer, plays a pivotal role in the expansion of the histology market. Histology and cytology techniques are essential for effective disease diagnosis and monitoring. For instance, a 2022 report by the National Library of Medicine estimated 1,918,030 new cancer cases and 609,360 cancer-related deaths in the United States, with nearly 350 daily deaths attributed to lung cancer, the leading cause of cancer mortality. In addition, continuous technological advancements in histology and cytology, including automation, digital pathology, and molecular pathology, are further fueling market growth.

It is estimated that in 2025 there will be a total of 226,650 new cases of lung and bronchus cancer in the United States. The highest number of these cases are estimated to be in the state of Florida. This statistic presents the estimated number of new lung and bronchus cancer cases in the United States in 2025, by state.

Context

COVID-19 Cases and Deaths by Race/Ethnicity

Content

COVID-19 cases and associated deaths that have been reported among Connecticut residents, broken down by race and ethnicity. All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. Deaths reported to either the Office of the Chief Medical Examiner (OCME) or Department of Public Health (DPH) are included in the COVID-19 update.

The following data show the number of COVID-19 cases and associated deaths per 100,000 population by race and ethnicity. Crude rates represent the total cases or deaths per 100,000 people. Age-adjusted rates consider the age of the person at diagnosis or death when estimating the rate and use a standardized population to provide a fair comparison between population groups with different age distributions. Age-adjustment is important in Connecticut as the median age of among the non-Hispanic white population is 47 years, whereas it is 34 years among non-Hispanic blacks, and 29 years among Hispanics. Because most non-Hispanic white residents who died were over 75 years of age, the age-adjusted rates are lower than the unadjusted rates. In contrast, Hispanic residents who died tend to be younger than 75 years of age which results in higher age-adjusted rates.

The age-adjusted rates are directly standardized using the 2018 ASRH Connecticut population estimate denominators (available here: https://portal.ct.gov/DPH/Health-Information-Systems--Reporting/Population/Annual-State--County-Population-with-Demographics).

Rates are standardized to the 2000 US Millions Standard population (data available here: https://seer.cancer.gov/stdpopulations/). Standardization was done using 19 age groups (0, 1-4, 5-9, 10-14, ..., 80-84, 85 years and older). More information about direct standardization for age adjustment is available here: https://www.cdc.gov/nchs/data/statnt/statnt06rv.pdf Categories are mutually exclusive. The category “multiracial” includes people who answered ‘yes’ to more than one race category. Counts may not add up to total case counts as data on race and ethnicity may be missing. Age-adjusted rates calculated only for groups with more than 20 deaths. Abbreviation: NH=Non-Hispanic.

This dataset will be updated on a daily basis. Data are subject to future revision as reporting changes.

Starting in July 2020, this dataset will be updated every weekday.

Additional notes: A delay in the data pull schedule occurred on 06/23/2020. Data from 06/22/2020 was processed on 06/23/2020 at 3:30 PM. The normal data cycle resumed with the data for 06/23/2020.

A network outage on 05/19/2020 resulted in a change in the data pull schedule. Data from 5/19/2020 was processed on 05/20/2020 at 12:00 PM. Data from 5/20/2020 was processed on 5/20/2020 8:30 PM. The normal data cycle resumed on 05/20/2020 with the 8:30 PM data pull. As a result of the network outage, the timestamp on the datasets on the Open Data Portal differs from the timestamp in DPH's daily PDF reports.

Acknowledgements

Thanks to catalog.data.gov.

Summary statistics for mean percent of daily smokers in the Mid-South states, 1999–2012.

In Terms of Revenue, The Pharmaceutical Industry market was the leading End User with 48.12% Share of total Global Sutherlandia Extract Market in 2021.

Middle East & Africa was the dominated region with 41.82% of total revenue market share in 2021. Increasing incidences of cancer and AIDS drive the growth of the sutherlandia extract market within the forecast period. Health professionals and community workers suggested that daily treatment with Sutherlandia can improve appetite, facilitate weight gain, and improve CD4 counts in HIV-positive patients. Colorectal cancer remains to be one of the leading causes of death across the world, with millions of patients diagnosed annually. For example, in 2022, around 1,918,563 new cancer cases and 609,363 cancer deaths occurred in the United States, including approximately 350 deaths per day from lung cancer. In addition, the growth of the sutherlandia extract market is driven by the rising use of herbal medicine in clinical treatment. It is estimated that nearly 80% of the world’s population is dependent on traditional herbal medicine for primary health care. However, sutherlandia extract has side effects that may affect the growth of the market. The government of various countries has taken several measures to promote the cultivation and export of medicinal plants will create numerous opportunities for the sutherlandia extract market during the forecast period. Sutherlandia frutescens extract is one of the most promising medicinal plants in South Africa that is used as an immune booster and a traditional treatment for cancer. Sutherlandia frutescens is also known as cancer bush. It has been also used in extract form for years to treat a variety of ailments including internal cancers, diabetes, uterine disease, influenza, HIV, depression, and arthritis.

The COVID-19 pandemic and resulting public health measures have had significant impacts on daily life, including shifts in health behaviours which contribute to weight gain and may increase subsequent risk of chronic diseases such as cancer. Using OncoSim, a web-based microsimulation tool, we estimated the future burden of cancer in Canada by incorporating data on unintentional weight gain among adults during the first year of the COVID-19 pandemic. Population impact measures were estimated until 2042, assuming a 12-year latency period. We estimated 14,194 excess cancer cases and 5,324 excess cancer deaths by 2042 due to COVID-19 related weight gain. Particularly large impacts were estimated for endometrial and breast cancer among women, with 2,983 and 2,151 excess cases by 2042. For men, 1,700 excess colorectal cases and 1,188 excess kidney cancer cases were projected by 2042. Changes in health behavior during the COVID-19 pandemic are likely to have significant and long-lasting impacts on cancer burden. These projections highlight the immediate need for investment into the development and implementation of effective cancer prevention strategies.

In 2023, there were approximately 750.5 deaths by all causes per 100,000 inhabitants in the United States. This statistic shows the death rate for all causes in the United States between 1950 and 2023. Causes of death in the U.S. Over the past decades, chronic conditions and non-communicable diseases have come to the forefront of health concerns and have contributed to major causes of death all over the globe. In 2022, the leading cause of death in the U.S. was heart disease, followed by cancer. However, the death rates for both heart disease and cancer have decreased in the U.S. over the past two decades. On the other hand, the number of deaths due to Alzheimer’s disease – which is strongly linked to cardiovascular disease- has increased by almost 141 percent between 2000 and 2021. Risk and lifestyle factors Lifestyle factors play a major role in cardiovascular health and the development of various diseases and conditions. Modifiable lifestyle factors that are known to reduce risk of both cancer and cardiovascular disease among people of all ages include smoking cessation, maintaining a healthy diet, and exercising regularly. An estimated two million new cases of cancer in the U.S. are expected in 2025.

Summary statistics of the mean percent of daily males and females smokers for 38 states and District of Columbia, 1999–2012.

Gastric cancer (GC) is one of the most malignant cancers and is estimated to be fifth in incidence ratio and the third leading cause of cancer death worldwide. Despite advances in GC treatment, poor prognosis and low survival rate necessitate the development of novel treatment options. Fibroblast growth factor receptors (FGFRs) have been suggested to be potential targets for GC treatment. In this study, we report a novel selective FGFR inhibitor, RK-019, with a pyrido [1, 2-a] pyrimidinone skeleton. In vitro, RK-019 showed excellent FGFR1-4 inhibitory activities and strong anti-proliferative effects against FGFR2-amplification (FGFR2-amp) GC cells, including SNU-16 and KATO III cells. Treatment with RK-019 suppressed phosphorylation of FGFR and its downstream pathway proteins, such as FRS2, PLCγ, AKT, and Erk, resulting in cell cycle arrest and induction of apoptosis. Furthermore, daily oral administration of RK-019 could attenuate tumor xenograft growth with no adverse effects. Here, we reported a novel specific FGFR inhibitor, RK-019, with potent anti-FGFR2-amp GC activity both in vitro and in vivo.

In 2023, the leading causes of death in Canada were malignant neoplasms (cancer) and diseases of the heart. Together, these diseases accounted for around ** percent of all deaths in Canada that year. COVID-19 was the sixth leading cause of death in Canada in 2023 with *** percent of deaths. The leading causes of death in Canada In 2023, around ****** people in Canada died from cancer, making it by far the leading cause of death in the country. In comparison, an estimated ****** people died from diseases of the heart, while ****** died from accidents. In 2023, the death rate for diabetes mellitus was **** per 100,000 population, making it the seventh leading cause of death. Diabetes is a growing problem in Canada, with around ***** percent of the population diagnosed with the disease as of 2023. What is the deadliest form of cancer in Canada? In Canada, lung and bronchus cancer account for the largest share of cancer deaths, followed by colorectal cancer. In 2023, the death rate for lung and bronchus cancer was **** per 100,000 population, compared to **** deaths per 100,000 population for colorectal cancer. However, although lung and bronchus cancer are the deadliest cancers for both men and women in Canada, breast cancer is the second-deadliest cancer among women, accounting for **** percent of all cancer deaths. Colorectal cancer is the second most deadly cancer among men in Canada, followed by prostate cancer. In 2023, colorectal cancer accounted for around **** percent of all cancer deaths among men in Canada, while prostate cancer was responsible for **** percent of such deaths.

Objectives: To examine the effect of smoking status, smoking intensity, duration of smoking cessation and age of smoking initiation on the risk of all-cause and cause-specific mortality among cardiovascular disease (CVD) patients.Design: A population-based prospective cohort study.Setting: The National Health Interview Survey (NHIS) in the U.S. that were linked to the National Death Index (NDI).Participants: 66,190 CVD participants ≥ 18 years of age who were interviewed between 1997 and 2013 in the NHIS linked to the NDI through December 31, 2015.Outcome Measures: The primary outcome was all-cause mortality and the secondary outcome was cause-specific mortality including CVD mortality and cancer mortality.Results: During the mean follow-up of 8.1 years, we documented 22,518 deaths (including 6,473 CVD deaths and 4,050 cancer deaths). In the overall CVD population, former and current smokers had higher risk of all-cause (Former smokers: hazard ratios (HRs), 1.26; 95% confidence interval (CI), 1.21–1.31, P < 0.001; Current smokers: HRs, 1.96; 95%CI, 1.86–2.07, P < 0.001), CVD (Former smokers: HRs, 1.12; 95%CI, 1.05–1.21, P = 0.001; Current smokers: HRs, 1.80; 95%CI, 1.64–1.97, P < 0.001) and cancer mortality (Former smokers: HRs, 1.49; 95%CI, 1.35–1.64, P < 0.001; Current smokers: HRs, 2.78; 95%CI, 2.49–3.09, P < 0.001) than never smokers. Furthermore, similar results were observed when the study subjects were stratified according to the type of CVD. Among current smokers, the risk for cancer mortality increased as the daily number of cigarettes increased, regardless of the specific type of CVD. However, the association of the risk for all-cause and CVD mortality with smoking intensity did not present a dose-response relationship. In participants with angina pectoris or stroke, smoking intensity was inversely associated with deaths from CVD. In addition, the risk for all-cause, CVD and cancer mortality declined as years of smoking cessation increased. Finally, the relative risk of all-cause mortality was not significantly different in individuals with a younger age of smoking initiation.Conclusions: CVD patients who are smokers have an increased risk of all-cause, CVD and cancer mortality, and the risk decreases significantly after quitting smoking. These data further provide strong evidence that supports the recommendation to quit smoking for the prevention of premature deaths among individuals with CVD.